Anika Therapeutics ANIK Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -9.8%+0.1pp | -9.9%+30.3pp | -40.2%+24.9pp | -65.1%-12.0pp | -53.1%-6.6pp | |
| Returns | ||||||
| Return on equity | -8%-0.5pp | -7.5%+12.7pp | -20.2%+13.6pp | -33.9%-2.1pp | -31.8%-1.0pp | |
| Return on assets | -6.1%-0.5pp | -5.7%+10.0pp | -15.7%+11.2pp | -26.9%-1.9pp | -25%-1.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.6×+0.2× | 0.4×0.0× | 0.4×-0.1× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.5×-0.3× | 4.7×-0.6× | 5.3×-0.9× | 6.2×+0.4× | 5.7×+0.8× | |
| Quick ratio | 3.4×-0.5× | 3.9×-0.6× | 4.5×-0.7× | 5.1×+0.6× | 4.5×+0.7× | |
| Cash ratio | 2×-0.7× | 2.6×-0.4× | 3×-0.3× | 3.3×+0.3× | 3×+0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Valuation | ||||||
| Market capitalization | $204.37M+31.6% | $138.59M+2.3% | $135.53M-15.8% | $161.05M-24.4% | $213.07M-11.6% | |
| Enterprise value | $189.09M+48.7% | $107.35M+5.2% | $102.05M-23.2% | $132.88M-28.2% | $185.13M-12.4% | |
| Price / sales | 1.8×+0.1× | 1.2×-0.4× | 1.6×-0.1× | 1.7×-0.3× | 2×0.0× | |
| Price / book | 1.5×+0.5× | 1×0.0× | 0.9×-0.2× | 1.1×-0.3× | 1.4×-0.1× | |
| EV / sales | 1.6×+0.3× | 1×-0.3× | 1.2×-0.2× | 1.4×-0.3× | 1.7×0.0× | |
| Earnings yield | -5.6%+33.5pp | -8.1%+16.3pp | -24.4%+13.3pp | -37.6%-11.0pp | -26.6%-3.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Anika Therapeutics's ratios come from?
- Every ratio is computed from Anika Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
